Literature DB >> 26423197

Does antiretroviral therapy reduce HIV-associated tuberculosis incidence to background rates? A national observational cohort study from England, Wales, and Northern Ireland.

Rishi K Gupta1, Brian Rice2, Alison E Brown2, H Lucy Thomas3, Dominik Zenner4, Laura Anderson3, Debora Pedrazzoli5, Anton Pozniak6, Ibrahim Abubakar7, Valerie Delpech2, Marc Lipman8.   

Abstract

BACKGROUND: Whether the incidence of tuberculosis in HIV-positive people receiving long-term antiretroviral therapy (ART) remains above background population rates is unclear. We compared tuberculosis incidence in people receiving ART with background rates in England, Wales, and Northern Ireland.
METHODS: We analysed a national cohort of HIV-positive individuals linked to the national tuberculosis register. Tuberculosis incidence in the HIV-positive cohort (2007-11) was stratified by ethnic origin and time on ART and compared with background rates (2009). Ethnic groups were defined as follows: the black African group included all individuals of black African origin, including those born in the UK and overseas; the white ethnic group included all white individuals born in the UK and overseas; the south Asian group included those of Indian, Pakistani, and Bangladeshi origin, born in the UK and overseas; and the other ethnic group included all other ethnic origins, including black Afro-Caribbeans.
FINDINGS: The HIV-positive cohort comprised 79 919 individuals, in whom there were 1550 incident cases in 231 664 person-years of observation (incidence 6·7 cases per 1000 person-years). Incidence of tuberculosis in the HIV-positive cohort was 13·6 per 1000 person-years in black Africans and 1·7 per 1000 person-years in white individuals. Incidence of tuberculosis during long-term ART (≥5 years) in black Africans with HIV was 2·4 per 1000 person-years, similar to background rates of 1·9 per 1000 person-years in this group (rate ratio 1·2, 95% CI 0·96-1·6; p=0·083); but in white individuals with HIV on long-term ART the incidence of 0·5 per 1000 person-years was higher than the background rate of 0·04 per 1000 person-years (rate ratio 14·5, 9·4-21·3; p<0·0001). The increased incidence relative to background in white HIV-positive individuals persisted when analysis was restricted to person-time accrued on ART with CD4 counts of at least 500 cells per μL and when white HIV-positive individuals born abroad were excluded.
INTERPRETATION: Tuberculosis incidence is unacceptably high irrespective of HIV status in black Africans. In white individuals with HIV, tuberculosis incidence is significantly higher than background rates in white people despite long-term ART. Expanded testing and treatment for latent tuberculosis infection to all HIV-infected adults, irrespective of ART status and CD4 cell count, might be warranted. FUNDING: Public Health England.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26423197     DOI: 10.1016/S2352-3018(15)00063-6

Source DB:  PubMed          Journal:  Lancet HIV        ISSN: 2352-3018            Impact factor:   12.767


  12 in total

1.  The link between tuberculosis and body mass index.

Authors:  Aaron R Casha; Marco Scarci
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

2.  TB preventive therapy for people living with HIV: key considerations for scale-up in resource-limited settings.

Authors:  I Pathmanathan; S Ahmedov; E Pevzner; G Anyalechi; S Modi; H Kirking; J S Cavanaugh
Journal:  Int J Tuberc Lung Dis       Date:  2018-06-01       Impact factor: 2.373

3.  Does antiretroviral treatment increase the infectiousness of smear-positive pulmonary tuberculosis?

Authors:  P Y Khan; A C Crampin; T Mzembe; O Koole; K L Fielding; K Kranzer; J R Glynn
Journal:  Int J Tuberc Lung Dis       Date:  2017-11-01       Impact factor: 2.373

4.  Enrichment of the airway microbiome in people living with HIV with potential pathogenic bacteria despite antiretroviral therapy.

Authors:  Sylvia A D Rofael; James Brown; Elisha Pickett; Margaret Johnson; John R Hurst; David Spratt; Marc Lipman; Timothy D McHugh
Journal:  EClinicalMedicine       Date:  2020-06-27

5.  Initiation and completion rates of isoniazid preventive therapy among people living with HIV in Far-Western Region of Nepal: a retrospective cohort study.

Authors:  Govinda Prasad Dhungana; Pruthu Thekkur; Palanivel Chinnakali; Usha Bhatta; Basudev Pandey; Wei-Hong Zhang
Journal:  BMJ Open       Date:  2019-05-29       Impact factor: 2.692

6.  Impact of HIV co-infection on the evolution and transmission of multidrug-resistant tuberculosis.

Authors:  Vegard Eldholm; Adrien Rieux; Johana Monteserin; Julia Montana Lopez; Domingo Palmero; Beatriz Lopez; Viviana Ritacco; Xavier Didelot; Francois Balloux
Journal:  Elife       Date:  2016-08-09       Impact factor: 8.140

7.  Immunological non-response and low hemoglobin levels are predictors of incident tuberculosis among HIV-infected individuals on Truvada-based therapy in Botswana.

Authors:  Lucy Mupfumi; Sikhulile Moyo; Kesaobaka Molebatsi; Prisca K Thami; Motswedi Anderson; Tuelo Mogashoa; Thato Iketleng; Joseph Makhema; Richard Marlink; Ishmael Kasvosve; Max Essex; Rosemary M Musonda; Simani Gaseitsiwe
Journal:  PLoS One       Date:  2018-01-31       Impact factor: 3.240

8.  Trends in, and factors associated with, HIV infection amongst tuberculosis patients in the era of anti-retroviral therapy: a retrospective study in England, Wales and Northern Ireland.

Authors:  Joanne R Winter; Helen R Stagg; Colette J Smith; Maeve K Lalor; Jennifer A Davidson; Alison E Brown; James Brown; Dominik Zenner; Marc Lipman; Anton Pozniak; Ibrahim Abubakar; Valerie Delpech
Journal:  BMC Med       Date:  2018-06-07       Impact factor: 8.775

9.  The effect of HIV status on the frequency and severity of acute respiratory illness.

Authors:  James Brown; Elisha Pickett; Colette Smith; Memory Sachikonye; Lucy Brooks; Tabitha Mahungu; David M Lowe; Sara Madge; Mike Youle; Margaret Johnson; John R Hurst; Timothy D McHugh; Ibrahim Abubakar; Marc Lipman
Journal:  PLoS One       Date:  2020-05-29       Impact factor: 3.240

10.  Plasma Biomarkers to Detect Prevalent or Predict Progressive Tuberculosis Associated With Human Immunodeficiency Virus-1.

Authors:  Maia Lesosky; Molebogeng X Rangaka; Cara Pienaar; Anna K Coussens; Rene Goliath; Shaheed Mathee; Judith Mwansa-Kambafwile; Gary Maartens; Robert J Wilkinson; Katalin Andrea Wilkinson
Journal:  Clin Infect Dis       Date:  2019-07-02       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.